Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Analysts are Increasing Price Targets of These 5 Stocks

In this article, we discuss the 5 stocks receiving price-target hikes from analysts. If you want to see more such stocks on the list, go directly to Analysts are Increasing Price Targets of These 10 Stocks.

5. Cardinal Health, Inc. (NYSE:CAH)

Number of Hedge Fund Holders: 45

Shares of Cardinal Health, Inc. (NYSE:CAH) advanced nearly two percent this morning after Credit Suisse lifted its price target for the healthcare services company from $64 per share to $79 per share. The research firm said the updated price target reflects the management’s commentary on the recent earnings call.

Earlier this month, Cardinal Health, Inc. (NYSE:CAH) reported better-than-expected financial results for its fiscal first quarter and reaffirmed its adjusted earnings outlook for the full year.

Speaking on the results, CEO of Cardinal Health, Inc. (NYSE:CAH), Jason Hollar, said:

“Our performance in the first quarter demonstrated stable fundamentals in the Pharmaceutical segment and tangible progress in the Medical segment. We are reaffirming our full year non-GAAP EPS guidance as we remain focused on our Medical Improvement Plan initiatives and building upon the growth of our Pharmaceutical business. Across the company, we are operating with urgency to drive our businesses forward and remain committed to creating shareholder value.”

Follow Cardinal Health Inc (NYSE:CAH)

4. Agilent Technologies, Inc. (NYSE:A)

Number of Hedge Fund Holders: 46

Agilent Technologies, Inc. (NYSE:A) delivered impressive financial results for its fiscal fourth quarter, sending its shares up more than six percent in the mid-day trading session on Tuesday, November 22.

Subsequently, several market research firms raised their price targets for Agilent Technologies, Inc. (NYSE:A) following the latest earnings beat. Jefferies lifted its price target for the life sciences company from $158 to $168, Wells Fargo increased its price target from $135 to $150 and Baird improved its price target from $160 to $170.

For its fiscal Q4, Agilent Technologies, Inc. (NYSE:A) reported adjusted earnings of $1.53 per share, up 26 percent over the year-ago period and above expectations of $1.39 per share. Revenue for the quarter also jumped 11 percent versus last year to $1.85 billion, topping estimates of $1.76 billion.

Follow Agilent Technologies Inc. (NYSE:A)

3. Dell Technologies Inc. (NYSE:DELL)

Number of Hedge Fund Holders: 49

Shares of Dell Technologies Inc. (NYSE:DELL) rose to a nearly three-month high after the opening bell on Tuesday, November 22. The surge came after Raymond James raised its price target for the tech company from $47 per share to $50 per share following its Q3 results.

Dell Technologies Inc. (NYSE:DELL) earned $2.30 per share on an adjusted basis in Q3, smashing expectations of $1.60 per share. The quarterly revenue of $24.7 billion was also above analysts’ average estimate of $24.4 billion.

Looking forward, Dell Technologies Inc. (NYSE:DELL) expects adjusted earnings in the range of $1.50 – $1.80 per share and revenue between $23 – $24 billion for the current quarter. The outlook compares with the consensus of $1.63 per share for earnings and $24.9 billion for revenue.

Follow Dell Technologies Inc. (NYSE:DELL)

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 75

Berenberg improved its price target for Eli Lilly and Company (NYSE:LLY) from $345 per share to $375 per share on Tuesday, November 22. The research firm acknowledged the solid underlying performance of the company despite currency challenges.

Separately, Eli Lilly and Company (NYSE:LLY) also appeared in the third-quarter 2022 investor letter of investment management firm ClearBridge Investments. Here’s what the firm said:

“In the U.S., we initiated a position in pharmaceutical maker Eli Lilly (NYSE:LLY) as it brings out new drug candidates for diabetes and Alzheimer’s disease. New drugs impact diabetes but have also demonstrated significant weight loss for patients who are overweight and have other co-morbidity issues as a result. Lilly is one of the two key players in diabetes care and we believe the potential market opportunity is much higher than the consensus forecasts as we are seeing evidence of accelerating adoption.”

Follow Eli Lilly & Co (NYSE:LLY)

1. Booking Holdings Inc. (NASDAQ:BKNG)

Number of Hedge Fund Holders: 92

Barclays lifted its price target for Booking Holdings Inc. (NASDAQ:BKNG) from $2,370 per share to $2,430 per share on Tuesday, November 22. Analyst Mario Lu now expects the global leisure travel industry to grow 12 percent in 2023. Lu revised his estimates following the Q3 earnings.

Earlier this month, Booking Holdings Inc. (NASDAQ:BKNG) posted impressive financial results for the third quarter. The travel technology company’s adjusted earnings climbed 41 percent on a year-over-year basis to $53.03 per share.

Follow Booking Holdings Inc. (NASDAQ:BKNG)

Revenue for the quarter also soared 29 percent versus last year to $6.1 billion. Analysts expected Booking Holdings Inc. (NASDAQ:BKNG) to earn $49.99 per share on revenue of $5.92 billion.

Discussing the results, CEO Glenn Fogel said in a statement:

“Despite the rising concern around the macroeconomic environment, we are encouraged by the slight improvement in room night growth we have seen in October and by the level of bookings for travel in early 2023.”

You can also take a peek at 10 Best Fundamental Stocks To Invest In and 12 Best Consumer Staple Stocks.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.